# NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma

> **NCT04594811** · PHASE1 · TERMINATED · sponsor: **NeoImmuneTech** · enrollment: 10 (actual)

## Conditions studied

- Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC)

## Interventions

- **DRUG:** NT-I7
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04594811
- **Lead sponsor:** NeoImmuneTech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-21
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Company strategic decision
- **Last updated:** 2024-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594811, "NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04594811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*